secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRINKS CO (BCO)
CIK:        0000078890
Form:       8-K
Filed at:   2026-10-08T10:00:54+00:00
Accession:  0000078890-26-000063
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Brink's receives CMA acceptance in principle of remedy for NCR Atleos acquisition
--------------------------------------------------------------------------------

- UK CMA accepted in principle Brink's proposed remedy to divest NoteMachine/TestLink UK, avoiding a CMA Phase 2 referral for the NCR Atleos acquisition.
- Brink's said the NCR Atleos acquisition remains on track to close early in Q1 2027, with sale process for NoteMachine/TestLink UK progressing and prospective buyers engaged.
- CEO Mark Eubanks said the remedy does not impact the $200 million in annual run-rate cost synergies expected within three years of closing the transaction.
- Brink's and NCR Atleos trade on NYSE under BCO and NATL, respectively.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/78890/000007889026000063/0000078890-26-000063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/78890/000007889026000063/bco-20261008.htm
  HTML page:      https://secwatch.observer/filing/0000078890-26-000063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer